Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Clinical trial NCT01485796 · COMPLETED

Trial details

NCT number: NCT01485796
Sponsor: Baxalta now part of Shire
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Primary Immunodeficiency Diseases (PID)

Start date: 2011-12-29
Primary completion: 2013-01-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.